Chiusura precedente | 5,0300 |
Aperto | 5,0700 |
Denaro | 4,7400 x 100 |
Lettera | 5,1100 x 100 |
Min-Max giorno | 4,7500 - 5,0999 |
Intervallo di 52 settimane | 1,5900 - 8,9000 |
Volume | |
Media Volume | 280.907 |
Capitalizzazione | 107,608M |
Beta (5 anni mensile) | 0,24 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -10,3000 |
Prossima data utili | 29 mar 2024 - 02 apr 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
Pharmaceutical and Academic Veteran Brings Significant Innovative Technology and Development Expertise Launching New Cellular TherapiesFLORHAM PARK, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies and advanced biomaterial products, today announced the appointment of Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors. Dr. Ling, a distinguished academic and
Celularity to provide research support for Regeneron's targeted, allogeneic, chimeric antigen receptor (CAR) T-cell therapyAgreement underscores Celularity's demonstrated expertise in cell therapy research FLORHAM PARK, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing allogeneic cell therapies and biomaterial products, announced today a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals, Inc.
FLORHAM PARK, N.J., July 27, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has entered into a definitive agreement with a single, healthcare-focused institutional investor for the purchase and sale of 8,571,428 shares of its Class A common stock together with warrants to purchase up to 8,571,428 shares of its Class A common stock at a combined